An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study. J of Skin [Internet]. 2019 Nov. 9 [cited 2025 Apr. 19];3:S12. Available from: https://skin.dermsquared.com/skin/article/view/739